The EMPRISE real-world evidence study

The EMPRISE (EMPagliflozin compaRative effectIveness and SafEty) real-world evidence (RWE) study was initiated in 2016 to complement the EMPA-REG OUTCOME^® trial. It aims to provide a clinical picture of empagliflozin in routine clinical care. This includes comparative effectiveness, safety and healthcare resource utilization and cost outcomes compared with commonly used dipeptidyl peptidase-4 (DPP-4) inhibitors in people with type 2 diabetes with and without cardiovascular disease. In addition, analyses have provided data on the effectiveness of empagliflozin compared with glucagon-like peptide-1 (GLP-1) receptor agonists.

The U.S. study assesses the first five years of empagliflozin use in the U.S. between 2014 to 2019. Over 200,000 people with type 2 diabetes from two commercial U.S. healthcare providers and Medicare are projected to be included by study completion. The U.S. EMPRISE RWE study was initiated, and is being led, by academic partners from the Division of Pharmacoepidemiology at Brigham and Women’s Hospital and Harvard Medical School. The study is part of an academic collaboration between Brigham and Women’s Hospital and Boehringer Ingelheim.

Started in 2019, additional EMPRISE RWE studies including over 130,000 people in Asia, Europe and Israel will provide insights from different regions of the world with an international perspective on the use of empagliflozin in routine clinical care. EMPRISE EU is analysing data collected in Sweden, Finland, Spain, Germany, and Israel; EMPRISE East Asia analyses real-world evidence from Japan, South Korea and Taiwan.
 

Learn more about the EMPRISE RWE study design and results: